Generic Elyxyb Availability
Last updated on Jan 8, 2025.
Elyxyb is a brand name of celecoxib, approved by the FDA in the following formulation(s):
ELYXYB (celecoxib - solution;oral)
-
Manufacturer: SCILEX PHARMS
Approval date: May 5, 2020
Strength(s): 25MG/ML [RLD]
Has a generic version of Elyxyb been approved?
No. There is currently no therapeutically equivalent version of Elyxyb available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Elyxyb. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Oral composition of celecoxib for treatment of pain
Patent 10,376,527
Issued: August 13, 2019
Inventor(s): Baheti Ankit & Padhi Bijay Kumar & Vakada Supritha & Raghuvanshi Rajeev Singh
Assignee(s): DR. REDDY'S LABORATORIES LTD.The present invention relates to a stable oral liquid pharmaceutical composition of celecoxib or its pharmaceutically acceptable salts thereof. The celecoxib present in the compositions as described herein do not show any precipitation when subjected in Fasted-State Simulated Gastric Fluid (FaSSGF) at pH 2.0, temperature of 37° C.±0.5° C. and under stirring at a speed of 50 rpm at least for 60 minutes. It also relates to the process of preparing and method of using said composition of celecoxib.
Patent expiration dates:
- May 27, 2036✓✓
- May 27, 2036
-
Oral composition of celecoxib for treatment of pain
Patent 10,722,456
Issued: July 28, 2020
Inventor(s): Munjal Sagar & Baheti Ankit & Padhi Bijay Kumar & Vakada Supritha & Raghuvanshi Rajeev Singh
Assignee(s): DR. REDDY'S LABORATORIES LTDThe present invention relates to a stable oral liquid pharmaceutical composition of celecoxib or pharmaceutically acceptable salts thereof. The celecoxib present in the compositions as described herein do not show any precipitation when subjected in Fasted-State Simulated Gastric Fluid (FaSSGF) at pH 2.0, temperature of 37° C.±0.5° C. and under stirring at a speed of 50 rpm at least for 60 minutes. It also relates to the process of preparing and method of using said composition of celecoxib.
Patent expiration dates:
- May 27, 2036✓✓
- May 27, 2036
-
Oral composition of celecoxib for treatment of pain
Patent 10,799,517
Issued: October 13, 2020
Inventor(s): Baheti Ankit & Padhi Bijay Kumar & Vakada Supritha & Raghuvanshi Rajeev Singh
Assignee(s): DR. REDDY'S LABORATORIES LTDThe present invention relates to a stable oral liquid pharmaceutical composition of celecoxib or its pharmaceutically acceptable salts thereof. The celecoxib present in the compositions as described herein do not show any precipitation when subjected in Fasted-State Simulated Gastric Fluid (FaSSGF) at pH 2.0, temperature of 37° C.±0.5° C. and under stirring at a speed of 50 rpm at least for 60 minutes. It also relates to the process of preparing and method of using said composition of celecoxib.
Patent expiration dates:
- May 27, 2036✓✓
- May 27, 2036
-
Oral composition of celecoxib for treatment of pain
Patent 9,572,819
Issued: February 21, 2017
Inventor(s): Baheti Ankit & Padhi Bijay Kumar & Vakada Supritha & Raghuvanshi Rajeev Singh
Assignee(s): Dr. Reddy's Laboratories, Ltd.The present invention relates to a stable oral liquid pharmaceutical composition of celecoxib or its pharmaceutically acceptable salts thereof. The celecoxib present in the compositions as described herein do not show any precipitation when subjected in Fasted-State Simulated Gastric Fluid (FaSSGF) at pH 2.0, temperature of 37° C.±0.5° C. and under stirring at a speed of 50 rpm at least for 60 minutes. It also relates to the process of preparing and method of using said composition of celecoxib.
Patent expiration dates:
- May 27, 2036✓✓
- May 27, 2036
-
Oral composition of celecoxib for treatment of pain
Patent 9,795,620
Issued: October 24, 2017
Inventor(s): Baheti Ankit & Padhi Bijay Kumar & Vakada Supritha & Raghuvanshi Rajeev Singh
Assignee(s): Dr. Reddy's Laboratories, Ltd.The present invention relates to a stable oral liquid pharmaceutical composition of celecoxib or its pharmaceutically acceptable salts thereof. The celecoxib present in the compositions as described herein do not show any precipitation when subjected in Fasted-State Simulated Gastric Fluid (FaSSGF) at pH 2.0, temperature of 37° C.±0.5° C. and under stirring at a speed of 50 rpm at least for 60 minutes. It also relates to the process of preparing and method of using said composition of celecoxib.
Patent expiration dates:
- May 27, 2036✓✓
- May 27, 2036
-
Oral composition of celecoxib for treatment of pain
Patent 9,949,990
Issued: April 24, 2018
Inventor(s): Baheti Ankit & Padhi Bijay Kumar & Vakada Supritha & Raghuvanshi Rajeev Singh
Assignee(s): DR. REDDY'S LABORATORIES LTD.The present invention relates to a stable oral liquid pharmaceutical composition of celecoxib or its pharmaceutically acceptable salts thereof. The celecoxib present in the compositions as described herein do not show any precipitation when subjected in Fasted-State Simulated Gastric Fluid (FaSSGF) at pH 2.0, temperature of 37° C.±0.5° C. and under stirring at a speed of 50 rpm at least for 60 minutes. It also relates to the process of preparing and method of using said composition of celecoxib.
Patent expiration dates:
- May 27, 2036✓✓
- May 27, 2036
More about Elyxyb (celecoxib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Latest FDA alerts (3)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: cox-2 inhibitors
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.